Actinium Pharmaceuticals (ATNM) Stock: Buy, Sell, or Hold?
ATNM - Actinium Pharmaceuticals, Inc
$1.60
0.22 (15.94%)
▲
5d:
+50.94%
30d:
+35.59%
90d:
+86.05%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 13, 2026
20d
Get Alerted When ATNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ATNM is 26.0% above its trading range ($1.27). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ATNM is 26.0% above its trading range ($1.27). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ATNM is currently trading at $1.60, which is considered extended relative to its 30-day fair value range of $1.07 to $1.27.
Technical Outlook: Technically, ATNM is in a uptrend. Immediate support is located at $0.95, while resistance sits at $1.66. The stock is showing strong short-term momentum, up 15.9% recently.
Market Sentiment: ATNM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.60 (+125.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATNM is in a uptrend. Immediate support is located at $0.95, while resistance sits at $1.66. The stock is showing strong short-term momentum, up 15.9% recently.
Market Sentiment: ATNM scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.60 (+125.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.07 -
$1.27
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+26.0% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+15.9%)
- BULLISH: Trading 125.0% below Wall St target ($3.60)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.07 -
$1.27
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.95
Resistance Level
$1.66
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.05
Wall Street Target
$3.60
(+125.0%)
Revenue Growth (YoY)
-100.0%
Profit Margin
32.2%
Share & Embed Analysis
Last updated: October 23, 2026 6:49 AM ET
Data refreshes hourly during market hours. Next update: 7:49 AM
Data refreshes hourly during market hours. Next update: 7:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATNM showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 68 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
